Dapagliflozin Benefits Heart Failure Patients, With or Without Diabetes
The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes, shows a study published in the New England Journal of Medicine.